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Hark, ye doctors of microbial mastery!
The Darwinian Domos of the medical world are indeed the
invisible instigators of infectious diseases. Not only have they been
indicted as the cause of such common maladies as dyspepsia, peptic
ulcer, and coronary artery disease, but now the Christmas Tree rash
with its herald patch, pityriasis rosea. In this issue, Watanabe and
colleagues add signi®cantly positive weight to the vacillating
balance of the causal role in pityriasis rosea of the human
herpesviruses 6 and 7 (HHV6 and HHV7).
150 years ago, the French dermatologist Gibert appropriately
named this rash for its scale of bran `pityriasiform', and its rose-red
hue, `rosea'. So distinctive and commonly observed was this rash
that it was inevitable that the pursuit of the protagonist of pityriasis
rosea began decades ago and subsequently centered on an infectious
agent, particularly a virus (Kempf and Burg, 2000). Over the last 5±
6 years studies have focused on HHV6 and primarily HHV7
(Drago et al, 1997, Kempf et al, 1999). Their contrasting
conclusions enhanced the interest, but not the clarity, of HHV6
and HHV7¢s causal role.
To understand why the research path attempting to assign disease
to these human herpesviruses is often convoluted and confused, one
must consider the character and conundrums of HHV6 and HHV7.
HHV6 was initially isolated in 1986 from patients with AIDS and
lymphoproliferative disorders (Salahuddin et al, 1986). Two years
later, Yamanishi et al isolated HHV6 from four infants with roseola
(Yamanishi et al, 1988). HHV7 was subsequently identi®ed
serendipitously in the cells of a healthy adult in 1990 by Frenkel
and colleagues (Frenkel et al, 1990).
The circumstances of the discovery of these two viruses were
prophetic for our current understanding of their clinical roles.
HHV6 is clearly associated with clinical primary infection mani-
fested by abrupt high fever and varying nonspeci®c signs, as well as
`the rash of roses' of exanthem subitum in children primarily
between 6 and 24 months of age (Hall et al, 1994; Yamanishi,
2001). In adults, clinical manifestations have been primarily
associated with reactivation in highly immunocompromised hosts.
HHV7, however, primarily remains a covert bystander. Primary
infection and clinical disease have rarely been recognized (Black
and Pellett, 1990). The few reported cases suggest clinical primary
infection is similar to HHV6 and may account for second cases of
roseola.
These two b-herpesviruses are remarkably similar, the closest
virologic siblings among the human herpesvirus family (Yamanishi,
2001; Black and Pellett, 1999). Both are acquired in early
childhood, resulting in universal infection. Both subsequently
become latent in peripheral blood mononuclear cells, saliva, and
other sites. The primary target for both viruses is the mature
CD4+ T-cell, which is the cell receptor for HHV7. Although
HHV7 antigen expressing cells are detectable in a wide number of
other sites, including skin, lungs, mammary glands, liver, and
kidney, HHV6 has the broader cellular tropism. This may relate to
the essential membrane receptor for HHV6 being CD46 which is
present on the surface of all nucleated cells (Yamanishi, 2001; Black
and Pellett, 1999). From these multiple sites both viruses may
reactivate. The importance of the similarity of curriculum vitae of
HHV6 and HHV7 is (1) the two are closely related virologically (2)
both cause universal infection early in life (3) each becomes latent
subsequently, and (4) they reactivate in older children and adults.
Thus, studies associating HHV6 and HHV7 disease in adults may
be confounded by the universal presence and detection of these
viruses from multiple sites, and presumably if they are responsible
for associated clinical manifestations, they are the result of
reactivation.
Our understanding of the pathogenesis of reactivation, however,
has been limited, as has been the technology to differentiate
productive (lytic) from latent or quiescent infection of persisting
virus.
Watanabe and colleagues have avoided some of these issues by
employing not only nested polymerase chain reaction (PCR) to
detect HHV6 and 7 DNA in skin, peripheral blood mononuclear
cells, serum, and saliva, but additionally used in situ hybridization to
identify viral mRNA expression and attempted visualization of
herpes virions in skin lesions by transmission electron microscopy.
HHV7 DNA was found in 93% of the lesions from pityriasis rosea
patients and also in 86% of their nonlesional skin samples. HHV6
DNA was also found in both lesional and nonlesional skin samples.
DNA of both viruses could also be detected in the few lesional and
nonlesional samples of controls, indicating the lack of diagnostic
speci®city of HHV6 or HHV7 DNA detection. But they further
demonstrated mRNA expression, and thus active replication, of
HHV7 in mononuclear cells of lesional skin specimens in 8 of 8
patients with pityriasis rosea, and HHV6 in 6 of the 8 specimens,
but in only 1 of 8 skin biopsies of healthy and psoriasis controls. Of
particular note, however, is the detection of HHV7 and HHV6
DNA in 100% and 88%, respectively, of serum samples from
pityriasis rosea patients, but from none of the serum specimens from
controls. These are new ®ndings which potentially offer new
insights into the conundrum of the persistence of HHV6 and
HHV7 subsequent to primary infection.
Presumably the productive infection arises from reactivation
since these patients most likely have been infected with both of
these viruses years previously in early childhood, although this was
not con®rmed serologically. However, the manifestations in these
pityriasis patients associated with reactivation are singular for hosts
with normal immunity. The detection of HHV6 and HHV7 in the
serum of these subjects with pityriasis rosea indicated concurrent
viremia and systemic infection. Viremia in previously infected
individuals, unless immunocompromised, is highly unusual (Hall et
al, 1994; Yamanishi, 2001; Black and Pellett, 1999). Furthermore,
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viremia with these viruses in our experience has been consistently
associated in immunologically normal hosts with appreciable fever
and systemic symptoms, which were not present in these subjects.
This is additionally confounded by the statement in the methods
that the authors only evaluated samples of serum that had a
b-globin positive control. Since this implies the presence of white
blood cells, the serum was not cell free, and the question of possible
contamination rises. Yet the serum from the control subjects which
presumably were also only assayed if b-globin controls were
present, did not contain the viral DNA, despite HHV7 DNA being
present in 82% of their peripheral blood mononuclear cells. These
results are not easily explained. Concurrent viral isolation from
serum samples could possibly have helped explain the above results,
as well as in situ hybridization of nonlesional samples from the
pityriasis patients or some further quantitative analysis of the type of
mononuclear cell in®ltration (i.e. T-cell, monocyte) in these
nonlesional samples.
Another intriguing aspect of this paper is the potential interaction
of HHV6 and HHV7 which has been demonstrated in vitro by
experiments showing that HHV7, but not HHV6, may be
reactivated from latently infected blood mononuclear cells by
T-cell activation. However, latent HHV6 could be recovered
when coinfection with HHV7 was established, suggesting HHV7
can provide a transacting function allowing the reactivation of
latent HHV6 (Tanaka-Taya et al, 2000; Katsafanas et al, 1996). We
have also shown in normal children that reactivation of one virus
may occur with primary infection of the other as demonstrated by
concurrent isolation of HHV6 and HHV7 from the peripheral
blood mononuclear cells of the children. Most frequently primary
HHV7 infection appears to elicit HHV6 reactivation, although the
opposite may also occur. These children, however, have con-
sistently shown systemic illness with high fevers.
The salient and piquant ®ndings of this article further suggest that
the potential interaction of these two viruses may be an important
mechanism of pathogenesis. Second, the reactivation of both
viruses associated with viremia in hosts with normal immunity is
singular. This could possibly result from primary infection of
HHV7 with reactivation of HHV6. However, this would seem
unlikely in view of the epidemiologic data demonstrating that
essentially all adults have had primary infection with both of these
viruses as children. More important is the question of whether these
®ndings of the association of HHV6 and HHV7 with pityriasis
rosea explain and expand our clinical observations of this disease:
Can they explain what triggers the abrupt occurence of this
exanthem which becomes widespread in a host harboring both
viruses since early childhood? Could this represent a particular host
susceptibility with the necessary cofactors of both viruses being
simultaneously present or a stress to the skin that results in local
diminished control of latent virus and local reactivation? Do these
capricious viruses explain the small number of recurrent pityriasis
cases (estimated at 3%) as being related to repetitive episodes of
reactivation? Conversely, can the 97% lack give clues to the
mechanism that keeps these parasitic viruses asymptomatic since
early childhood? Could recurrent cases or the clinical variations of
pityriasis rosea possibly be associated with the reactivation of
different strains of HHV6, variant A and variant B, or of a
difference in the viral loads of HHV7 vs. HHV6? Are the characters
of these two viruses, as we currently view them, compatible with
pityriasis rosea's age, predilection, prolonged course, and the herald
patch that lights the Christmas Tree, but remains its most
prominent star? There may be no consensus on whether the
answer is yes of no, but certainly as to whether more research is
necessary.
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